 |
市場調査レポート
商品コード
1463405
リキッドバイオプシーの世界市場規模、シェア、成長分析、タイプ別、エンドユーザー別 - 産業予測、2024～2031年Global Liquid Biopsy Market Size, Share, Growth Analysis, By Type(Reagents and Kits, and Instruments), By End-User(Hospitals and Clinics, and Research Centres) - Industry Forecast 2024-2031 |
||||||
| リキッドバイオプシーの世界市場規模、シェア、成長分析、タイプ別、エンドユーザー別 - 産業予測、2024～2031年 |
|
出版日: 2024年04月09日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界のリキッドバイオプシーの市場規模は、2022年に94億米ドルとなり、2023年の106億9,000万米ドルから、2031年までには298億5,000万米ドルに成長し、予測期間（2024～2031年）のCAGRは13.7%で成長する見通しです。
市場拡大の主要な要因は、がん罹患率の上昇と侵襲性の低い診断手技に対する需要の急増です。米国では、非小細胞肺がんが最も流行しています。分析によると、2021年には235,760人以上が非小細胞肺がんの診断を受けました。リキッドバイオプシー検査は、一般集団におけるがんの診断と治癒の手段として需要が高まっています。簡単で安全な家庭内アクセスを提供する企業のアプローチも、市場の拡大を後押ししています。例えば、情報サービスプロバイダーのNeoGenomics, Inc.は2020年11月にNeoLABとInvisionFirstの立ち上げを発表しました。これはリキッドバイオプシー検査のモバイル瀉血サービスです。同組織はExamOneとMetro Health Staffing LLCを通じてサービスを提供し、検査の効果的な実施を保証しています。リキッドバイオプシーは、従来のスクリーニング検査に代わる効果的な検査法を提供することで、がんの早期発見と疾病予防を促進しようとしています。その性質は実に繊細です。血液検査の結果は、病態の重症度や推奨される治療方針に関する情報を提供します。したがって、市場の拡大は、製薬業界やバイオテクノロジー業界における研究開発活動の増加や、さまざまな研究プロジェクトに対する政府資金の増加によって刺激されています。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次・一次情報源
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主要な投資の分析
- 主要な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
リキッドバイオプシーの世界市場：タイプ別
- 市場概要
- 試薬・キット
- 機器
リキッドバイオプシーの世界市場：エンドユーザー別
- 市場概要
- 病院・診療所
- 研究センター
リキッドバイオプシーの世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主要な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- F. Hoffmann-La Roche Ltd（Switzerland）
- Thermo Fisher Scientific Inc.（US）
- QIAGEN N.V.（Netherlands）
- Illumina, Inc.（US）
- Guardant Health, Inc.（US）
- Biocept, Inc.（US）
- Sysmex Corporation（Japan）
- Menarini Silicon Biosystems（Italy）
- Natera, Inc.（US）
- GRAIL, Inc.（US）
- Biocartis Group NV（Belgium）
- Personal Genome Diagnostics Inc.（US）
- Exosome Diagnostics, Inc.（US）
- Bio-Rad Laboratories, Inc.（US）
- Genomic Health, Inc.（US）
- RainDance Technologies, Inc.（US）
- OncoCyte Corporation（US）
- Adaptive Biotechnologies Corporation（US）
- Angle plc（United Kingdom）
- Epic Sciences, Inc.（US）
Global Liquid Biopsy Market size was valued at USD 9.4 billion in 2022 and is poised to grow from USD 10.69 billion in 2023 to USD 29.85 billion by 2031, growing at a CAGR of 13.7% during the forecast period (2024-2031).
The primary drivers of the market's expansion are the rising incidence of cancer and the sharp rise in demand for less invasive diagnostic procedures. In the United States, non-small cell lung cancer is the most prevalent type of the disease. An analysis revealed that in 2021, over 235,760 persons will receive a non-small cell lung cancer diagnosis. Liquid biopsy tests are in greater demand as a means of diagnosing and curing cancer in the general population. The approach taken by businesses to provide simple and secure in-home access also propels the market's expansion. For example, the information services provider NeoGenomics, Inc. announced the launch of NeoLAB and InvisionFirst in November 2020.It is a liquid biopsy testing mobile phlebotomy service. The organization provides its services via ExamOne and Metro Health Staffing LLC to guarantee that exams are administered effectively. By providing an effective substitute for conventional screening, liquid biopsy seeks to promote early cancer detection and disease prevention. Their nature is really sensitive. The blood test results provide information about the severity of the condition and the recommended course of treatment. Therefore, the expansion of the market is stimulated by an increase in R&D activities in the pharmaceutical and biotechnology industries as well as an increase in government funding for various research projects.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liquid Biopsy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Liquid Biopsy Market Segmental Analysis
The Global Liquid Biopsy market is segmented by type, end-user, and region. Based on type, the market can be segmented into reagents and kits, and instruments. Based on end-user, the market is segmented into hospitals and clinics segment, and research centres. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global Liquid Biopsy Market
The need for early detection and the rising incidence of cancer are two main factors propelling the worldwide liquid biopsy market's expansion. Early cancer diagnosis and treatment are time-consuming, intrusive procedures that can make patients uncomfortable. Furthermore, the industry is growing thanks to the application of cutting-edge liquid biopsy testing for cancer diagnosis. A less intrusive and uncomfortable method for cancer monitoring and diagnosis is the liquid biopsy. Additionally, the liquid biopsy test aids in the early detection of cancer. As a result, these elements stimulate market expansion and raise demand for liquid biopsy tests.
Restraints in the Global Liquid Biopsy Market
The absence of standardization and regulatory norms for liquid biopsy tests impedes the market's expansion. Liquid biopsy test approval is a complex and time-consuming process regulated by regulations. The introduction of new products onto the market is further delayed by this. The market's expansion is further hampered by the expensive nature of liquid biopsy testing and the narrow coverage of reimbursements. These difficulties may be addressed with the introduction of defined criteria and expanded reimbursement coverage for liquid biopsy tests.
Market Trends of the Global Liquid Biopsy Market
One of the major developments in the global liquid biopsy market is the growing use of next-generation sequencing technology. RNA and DNA molecules may be sequenced at high throughput with the NGS, making it possible to identify cancer biomarkers from a single sample. This technique is mostly utilized in liquid biopsy procedures with the goal of delivering extremely sensitive and specific data for cancer monitoring and early diagnosis. As a result, the market is expanding due to the spike in demand for NGS liquid biopsy tests.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Liquid Biopsy Market by Type
- Market Overview
- Reagents and Kits
- and Instruments
Global Liquid Biopsy Market by End-User
- Market Overview
- Hospitals and Clinics
- and Research Centres
Global Liquid Biopsy Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- QIAGEN N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Guardant Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biocept, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Menarini Silicon Biosystems (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Natera, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GRAIL, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biocartis Group NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Personal Genome Diagnostics Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Exosome Diagnostics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genomic Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- RainDance Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- OncoCyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Adaptive Biotechnologies Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Angle plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Epic Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
